|Day Low/High||84.84 / 85.83|
|52 Wk Low/High||55.36 / 90.61|
It's one of the most hated members of the Dow -- WBA -- and it's set to outperform.
I am talking about themes that can stand the test not of today, or tomorrow, but for all of 2021 and beyond.
We have to take both the private sector and the states out of the equation, and adopt the process that wiped out Polio.
From Amazon to Zoom, here are my prognostications and best ideas for the new year.
In 2021, let's support each other as we fight our way out of this mess. Let's learn how to love, and forget how to hate.
The stock hasn't done much of late, but perhaps FedEx's earnings report Thursday will offer clues of what's going on in delivery.
The Russell 2000 is now up 7% for December, twice the increase for the Nasdaq Composite.
Vaccines are on the move (a big plus) even as members of Congress continue to dawdle on a fiscal support package (a big minus).
A look at the fast-growing field of telehealth, both for people and, as a less-well known market, for pets.
The RMPIA also tops other indexes for year, shooting ahead 29%.
The battle to gain control over Covid-19 is entering a crucial stage and calls for continued determination.
None of these questions have been answered which is why I see chaos ahead as we can't even imagine this process working.
Basically, I think we laid out enough reasons for financial markets to revolt, yet they did not.
I'm long HD. Despite today's drop, I do not yet see this as a buying opportunity.
I've got 16 names to consider -- and one that's really a crafty one.
The firm's Q3 earnings easily beat Wall Street's expectations.
Plus, the rising possibility that the Senate may not remain in Republican control should give investors pause.
The average declined in October, but it was less than that hit took by the major indexes.
While the market appears to be enjoying the election results (so far), here's my take on electric vehicles, health care, metals and restaurants.
Several sessions over the past 10 days have seen increased trading volume at the NYSE, but not the Nasdaq, and for the S&P 500, but not the Nasdaq Composite. Is this professional risk reduction?
Shares of the fitness beverage maker look stuck in a sideways pattern after a big run higher amid what is likely profit taking.
The RMPIA rose 13.8% during the quarter, leaving it up just shy of 29% on a year-to-date basis, thanks to performance by CRM, AAPL , NKE and TMO.
New rapid tests and the effectiveness of universal mask wearing give hope while we wait on the elusive vaccine.
Neither candidate seems to be the enemy of the market -- at least not yet.
Abbott Labs can bring back some normalcy to this country -- and the world -- with its BinaxNOW rapid antigen test along with its amazing Navica app.
Follow fundamentals and ignore the attempts to gaslight you into not believing your own projections.